These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 26216974)

  • 1. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus.
    Corti D; Zhao J; Pedotti M; Simonelli L; Agnihothram S; Fett C; Fernandez-Rodriguez B; Foglierini M; Agatic G; Vanzetta F; Gopal R; Langrish CJ; Barrett NA; Sallusto F; Baric RS; Varani L; Zambon M; Perlman S; Lanzavecchia A
    Proc Natl Acad Sci U S A; 2015 Aug; 112(33):10473-8. PubMed ID: 26216974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient.
    Niu P; Zhang S; Zhou P; Huang B; Deng Y; Qin K; Wang P; Wang W; Wang X; Zhou J; Zhang L; Tan W
    J Infect Dis; 2018 Sep; 218(8):1249-1260. PubMed ID: 29846635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.
    Li Y; Wan Y; Liu P; Zhao J; Lu G; Qi J; Wang Q; Lu X; Wu Y; Liu W; Zhang B; Yuen KY; Perlman S; Gao GF; Yan J
    Cell Res; 2015 Nov; 25(11):1237-49. PubMed ID: 26391698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection.
    Qiu H; Sun S; Xiao H; Feng J; Guo Y; Tai W; Wang Y; Du L; Zhao G; Zhou Y
    Antiviral Res; 2016 Aug; 132():141-8. PubMed ID: 27312105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
    Malczyk AH; Kupke A; Prüfer S; Scheuplein VA; Hutzler S; Kreuz D; Beissert T; Bauer S; Hubich-Rau S; Tondera C; Eldin HS; Schmidt J; Vergara-Alert J; Süzer Y; Seifried J; Hanschmann KM; Kalinke U; Herold S; Sahin U; Cichutek K; Waibler Z; Eickmann M; Becker S; Mühlebach MD
    J Virol; 2015 Nov; 89(22):11654-67. PubMed ID: 26355094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.
    Kim MH; Kim HJ; Chang J
    PLoS One; 2019; 14(7):e0220196. PubMed ID: 31329652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset.
    de Wit E; Feldmann F; Horne E; Okumura A; Cameroni E; Haddock E; Saturday G; Scott D; Gopal R; Zambon M; Corti D; Feldmann H
    Antiviral Res; 2019 Mar; 163():70-74. PubMed ID: 30684561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain.
    Zhou Y; Yang Y; Huang J; Jiang S; Du L
    Viruses; 2019 Jan; 11(1):. PubMed ID: 30646569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection.
    Han HJ; Liu JW; Yu H; Yu XJ
    Viruses; 2018 Nov; 10(12):. PubMed ID: 30513619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein.
    Widjaja I; Wang C; van Haperen R; Gutiérrez-Álvarez J; van Dieren B; Okba NMA; Raj VS; Li W; Fernandez-Delgado R; Grosveld F; van Kuppeveld FJM; Haagmans BL; Enjuanes L; Drabek D; Bosch BJ
    Emerg Microbes Infect; 2019; 8(1):516-530. PubMed ID: 30938227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein.
    Chen Y; Lu S; Jia H; Deng Y; Zhou J; Huang B; Yu Y; Lan J; Wang W; Lou Y; Qin K; Tan W
    Emerg Microbes Infect; 2017 May; 6(5):e37. PubMed ID: 28536429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization.
    Kleine-Weber H; Elzayat MT; Wang L; Graham BS; Müller MA; Drosten C; Pöhlmann S; Hoffmann M
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.
    Tai W; Zhao G; Sun S; Guo Y; Wang Y; Tao X; Tseng CK; Li F; Jiang S; Du L; Zhou Y
    Virology; 2016 Dec; 499():375-382. PubMed ID: 27750111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset.
    Chen Z; Bao L; Chen C; Zou T; Xue Y; Li F; Lv Q; Gu S; Gao X; Cui S; Wang J; Qin C; Jin Q
    J Infect Dis; 2017 Jun; 215(12):1807-1815. PubMed ID: 28472421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of candidate vaccine approaches for MERS-CoV.
    Wang L; Shi W; Joyce MG; Modjarrad K; Zhang Y; Leung K; Lees CR; Zhou T; Yassine HM; Kanekiyo M; Yang ZY; Chen X; Becker MM; Freeman M; Vogel L; Johnson JC; Olinger G; Todd JP; Bagci U; Solomon J; Mollura DJ; Hensley L; Jahrling P; Denison MR; Rao SS; Subbarao K; Kwong PD; Mascola JR; Kong WP; Graham BS
    Nat Commun; 2015 Jul; 6():7712. PubMed ID: 26218507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein.
    Jiang L; Wang N; Zuo T; Shi X; Poon KM; Wu Y; Gao F; Li D; Wang R; Guo J; Fu L; Yuen KY; Zheng BJ; Wang X; Zhang L
    Sci Transl Med; 2014 Apr; 6(234):234ra59. PubMed ID: 24778414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection.
    Pascal KE; Coleman CM; Mujica AO; Kamat V; Badithe A; Fairhurst J; Hunt C; Strein J; Berrebi A; Sisk JM; Matthews KL; Babb R; Chen G; Lai KM; Huang TT; Olson W; Yancopoulos GD; Stahl N; Frieman MB; Kyratsous CA
    Proc Natl Acad Sci U S A; 2015 Jul; 112(28):8738-43. PubMed ID: 26124093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development.
    Mubarak A; Alturaiki W; Hemida MG
    J Immunol Res; 2019; 2019():6491738. PubMed ID: 31089478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.